April 17 (Reuters) - Nurix Therapeutics Inc NRIX.O:
NURIX ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR GS-6791/NX-0479 - A NOVEL IRAK4 DEGRADER FOR INFLAMMATORY CONDITIONS
NURIX THERAPEUTICS INC - GILEAD TO BEGIN PHASE 1 STUDY IN Q2 2025
NURIX THERAPEUTICS INC - TO RECEIVE $5 MILLION MILESTONE PAYMENT FROM GILEAD
NURIX THERAPEUTICS INC - ELIGIBLE FOR $420 MILLION IN FUTURE MILESTONES
Source text: ID:nGNX9p7cxX
Further company coverage: NRIX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.